Misusing a patentee’s market power
The Court of General Instance (formerly (?) the EU’s CFI) has upheld the European Commission’s ruling that AstraZeneca abused its dominant position in the market by practices designed to block or delay...
View ArticleFive Judges speak with one voice on Australian Patent Law Construction and...
The Rosuvastatin case is that rare beast - a decision of a 5 member Full Bench of the Federal Court. It canvases many issues and, no doubt, we shall be picking over it for years to come. Susan Gatford,...
View ArticleRosuvastatin goes to the High Court
The High Court has allowed special leave to appeal from the Full Federal Court's decision in AstraZeneca v Apotex ("Rosuvastatin").
View ArticleCommonwealth seeks $60 million on the undertaking as to damages
Sanofi sued Apotex (then known as GenRx) for infringement of its “clopidogrel patent”. It obtained interlocutory injunctions against Apotex against the sale of Apotex’ product and preventing Apotex...
View Article
More Pages to Explore .....